Eli Lilly applies for listing cancellation on London Stock Exchange Eli Lilly announced that it has applied for the cancellation of the listing of its shares of common stock on the London Stock Exchange, to take effect on March 27, 2013.
Leerink biopharma analysts hold an analyst/industry conference call Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
Eli Lilly upgraded at Goldman As previously reported, Goldman upgraded Eli Lilly to Neutral from Sell. The firm upgraded shares based on new product launches and pipeline assets, and cost reductions. Price target is $70.